HomeAI · summaries
Storia in 4 fonti
US stocks: Capricor shares 77% soar as potential FDA lifeline revives Duchenne drug hopes
Capricor Therapeutics shares surged significantly after the FDA agreed to review new drug data. The company had faced setbacks last month regarding its experimental Duchenne muscular dystrophy treatment. New 24-month data will focus on improving upper limb muscle function for the drug. Analysts view the FDA's willingness to review this information as a positive development. Capricor is pacing commercial launch spending while awaiting regulatory clarity on the drug.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
The FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the…
- ·
benzinga.com
Capricor Therapeutics Shares Surge 67.22% After Hours - Capricor Therapeutics (NASDAQ:CAPR)
Capricor Therapeutics shares surged 67.22% after hours following quarterly results and an update on the FDA review of its application.
